500568-76-3

Basic information

• Product Name: Phenol, 4-[[[2-chloro-9-(1-methylethyl)-9H-purin-6-yl]amino]methyl]-
• CAS NO: 500568-76-3
• Molecular Formula: C15H16ClN5O
• Molecular Weight: 317.778
• Mol File: 500568-76-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Phenol, 4-[[[2-chloro-9-(1-methylethyl)-9H-purin-6-yl]amino]methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 4-[[[2-chloro-9-(1-methylethyl)-9H-purin-6-yl]amino]methyl]-(500568-76-3)
• EPA Substance Registry System: Phenol, 4-[[[2-chloro-9-(1-methylethyl)-9H-purin-6-yl]amino]methyl]-(500568-76-3)

Safety Data

• Hazardous Substances Data: 500568-76-3(Hazardous Substances Data)

Upstream product

• 5451-40-1 2,6-dichloro-7H-purine 
• 5451-40-1 2,6 dichloropurine 
• 696-60-6 4-aminomethylphenol 
• 203436-45-7 2,6-dichloro-9-isopropyl-9H-purine 

Downstream Products

• 1427518-50-0 C₁₉H₂₅N₇O 

Relevant articles and documents

Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases

Several inhibitors of cyclin-dependent kinases (CDKs), including the 2,6,9-trisubstituted purine derivative roscovitine, are currently being evaluated in clinical trials as potential anticancer drugs. Here, we describe a new series of roscovitine derivatives that show increased potency in vitro. The series was tested for cytotoxicity against six cancer cell lines and for inhibition of CDKs. For series bearing 2-(hydroxyalkylamino) moiety, cytotoxic potency strongly correlated with anti-CDK2 activity. Importantly, structural changes that increase biochemical and anticancer activities of these compounds also increase elimination half-life. The most potent compounds were investigated further to assess their ability to influence cell cycle progression, p53-regulated transcription and apoptosis. All the observed biological effects were consistent with inhibition of CDKs involved in the regulation of cell cycle and transcription.

Synthesis and biological activity of olomoucine II.

Based on our previous experiences with synthesis of purines, novel 2,6,9-trisubstituted purine derivatives were prepared and assayed for the ability to inhibit CDK1/cyclin B kinase. One of newly synthesized compounds designated as olomoucine II, 6-[(2-hydroxybenzyl)amino]-2-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine, displays 10 times higher inhibitory activity than roscovitine, potent and specific CDK1 inhibitor. Olomoucine II in vitro cytotoxic activity exceeds purvalanol A, the most potent CDK inhibitor, as it kills the CEM cells with IC(50) value of 3.0 microM.